Ignite Creation Date:
2025-12-26 @ 10:32 AM
Ignite Modification Date:
2026-02-24 @ 12:14 AM
Study NCT ID:
NCT04097028
Status:
COMPLETED
Last Update Posted:
2025-04-29
First Post:
2019-09-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
Sponsor:
Roswell Park Cancer Institute
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | View |
| None | Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | View |
| None | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8 | View |
| None | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8 | View |
| None | Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | View |
Keywords: